
## P Willem Kamphuisen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5393140/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model. European Respiratory Journal, 2016, 48, 780-786.	6.7	199
2	Long-term Clinical Outcomes of Splanchnic Vein Thrombosis. JAMA Internal Medicine, 2015, 175, 1474.	5.1	180
3	Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. Blood, 2020, 136, 1433-1441.	1.4	106
4	Coagulation activation and microparticle-associated coagulant activity in cancer patients. Thrombosis and Haemostasis, 2012, 108, 160-165.	3.4	90
5	Effect of Statins on Venous Thromboembolic Events: A Meta-analysis of Published and Unpublished Evidence from Randomised Controlled Trials. PLoS Medicine, 2012, 9, e1001310.	8.4	78
6	Cardiovascular risk assessment in haemophilia patients. Thrombosis and Haemostasis, 2011, 105, 274-278.	3.4	71
7	Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry. Lancet Haematology,the, 2016, 3, e267-e275.	4.6	55
8	Haemostatic Profiles are Similar across All Aetiologies of Cirrhosis. Thrombosis and Haemostasis, 2019, 119, 246-253.	3.4	52
9	Clinical decision rule and D-dimer have lower clinical utility to exclude pulmonary embolism in cancer patients. Thrombosis and Haemostasis, 2010, 104, 831-836.	3.4	41
10	Renal Impairment, Recurrent Venous Thromboembolism and Bleeding in Cancer Patients with Acute Venous Thromboembolism—Analysis of the CATCH Study. Thrombosis and Haemostasis, 2018, 118, 914-921.	3.4	37
11	Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: a systematic review and meta-analysis. Blood Advances, 2020, 4, 5215-5225.	5.2	35
12	Comparison of 4- and 64-slice CT scanning in the diagnosis of pulmonary embolism. Thrombosis and Haemostasis, 2010, 103, 242-246.	3.4	30
13	Systolic Heart Failure: A Prothrombotic State. Seminars in Thrombosis and Hemostasis, 2009, 35, 497-504.	2.7	26
14	Venous Thrombosis at Unusual Sites and the Role of Thrombophilia. Seminars in Thrombosis and Hemostasis, 2007, 33, 582-587.	2.7	23
15	Evaluation of coagulation activation after Rhinovirus infection in patients with asthma and healthy control subjects: an observational study. Respiratory Research, 2014, 15, 14.	3.6	21
16	Nonâ€steroidal antiâ€inflammatory drugs and risk of pulmonary embolism. Pharmacoepidemiology and Drug Safety, 2011, 20, 635-642.	1.9	19
17	Management Strategies for Optimal Control of Anticoagulation in Patients with Atrial Fibrillation. Seminars in Thrombosis and Hemostasis, 2009, 35, 560-567.	2.7	17
18	Is a normal computed tomography pulmonary angiography safe to rule out acute pulmonary embolism in patients with a likely clinical probability?. Thrombosis and Haemostasis, 2017, 117, 1622-1629.	3.4	17

P WILLEM KAMPHUISEN

#	Article	IF	CITATIONS
19	A worldwide survey to assess the current approach to the treatment of patients with cancer and venous thromboembolism. Thrombosis and Haemostasis, 2013, 110, 959-965.	3.4	16
20	European guidelines on perioperative venous thromboembolism prophylaxis. European Journal of Anaesthesiology, 2018, 35, 139-141.	1.7	16
21	Thrombolysis for Pulmonary Embolism and Venous Thrombosis: Is It Worthwhile?. Seminars in Thrombosis and Hemostasis, 2007, 33, 821-828.	2.7	15
22	Anticoagulant activity of edoxaban in patients with cirrhosis. Blood, 2020, 136, 1561-1564.	1.4	14
23	Management and outcome of major bleeding in patients receiving vitamin K antagonists for venous thromboembolism. Thrombosis Research, 2018, 171, 74-80.	1.7	11
24	Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAMe-TT2-R2 Score: An Analysis of Hokusai-VTE. Thrombosis and Haemostasis, 2019, 119, 675-684.	3.4	9
25	Hemostatic Abnormalities and Arterial Thrombosis. Seminars in Thrombosis and Hemostasis, 2009, 35, 449-450.	2.7	2
26	Dabigatran-related coagulopathy: when can we assume the effect has "worn off�. American Journal of Emergency Medicine, 2014, 32, 1433-1434.	1.6	1
27	Letter to the Editor. Journal of Intensive Care Medicine, 2016, 31, 70-71.	2.8	0
28	Statin Treatment Reduces the Incidence of Recurrent Pulmonary Embolism: a Population Based Case-Control Study. Blood, 2010, 116, 808-808.	1.4	0